These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 24565471

  • 1. Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.
    Díaz-López A, Bulló M, Chacón MR, Estruch R, Vendrell J, Díez-Espino J, Fitó M, Corella D, Salas-Salvadó J.
    Cardiovasc Diabetol; 2014 Feb 24; 13():51. PubMed ID: 24565471
    [Abstract] [Full Text] [Related]

  • 2. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.
    Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2009 Jan 24; 4(1):110-8. PubMed ID: 18945991
    [Abstract] [Full Text] [Related]

  • 3. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
    Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2011 Dec 24; 219(2):892-9. PubMed ID: 21962403
    [Abstract] [Full Text] [Related]

  • 4. Age-associated increase in abdominal obesity and insulin resistance, and usefulness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japanese elderly with type 2 diabetes mellitus.
    Sakurai T, Iimuro S, Araki A, Umegaki H, Ohashi Y, Yokono K, Ito H.
    Gerontology; 2010 Dec 24; 56(2):141-9. PubMed ID: 19828932
    [Abstract] [Full Text] [Related]

  • 5. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.
    Díaz-López A, Chacón MR, Bulló M, Maymó-Masip E, Martínez-González MA, Estruch R, Vendrell J, Basora J, Díez-Espino J, Covas MI, Salas-Salvadó J.
    J Clin Endocrinol Metab; 2013 Aug 24; 98(8):3482-90. PubMed ID: 23760626
    [Abstract] [Full Text] [Related]

  • 6. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
    Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ.
    Clin J Am Soc Nephrol; 2011 Apr 24; 6(4):785-92. PubMed ID: 21330486
    [Abstract] [Full Text] [Related]

  • 7. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
    Fernández-Laso V, Sastre C, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2016 Mar 07; 11(3):413-22. PubMed ID: 26728587
    [Abstract] [Full Text] [Related]

  • 8. Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.
    Fernández-Laso V, Sastre C, Valdivielso JM, Fernández E, Martín-Ventura JL, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2015 Apr 07; 239(2):358-63. PubMed ID: 25681674
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
    Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR.
    PLoS One; 2012 Apr 07; 7(8):e43919. PubMed ID: 22937125
    [Abstract] [Full Text] [Related]

  • 10. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction.
    García-Cruz E, Leibar-Tamayo A, Romero J, Piqueras M, Luque P, Cardeñosa O, Alcaraz A.
    J Sex Med; 2013 Oct 07; 10(10):2529-38. PubMed ID: 23898860
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of the metabolic syndrome in patients with carotid disease according to NHLBI/AHA and IDF criteria: a cross-sectional study.
    Maksimovic MZ, Vlajinac HD, Radak DJ, Marinkovic JM, Jorga JB.
    BMC Cardiovasc Disord; 2012 Jan 31; 12():2. PubMed ID: 22292476
    [Abstract] [Full Text] [Related]

  • 12. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
    Rusu CC, Racasan S, Kacso IM, Ghervan L, Moldovan D, Potra A, Patiu IM, Bondor C, Caprioara MG.
    Int Urol Nephrol; 2015 Dec 31; 47(12):2023-30. PubMed ID: 26433887
    [Abstract] [Full Text] [Related]

  • 13. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease.
    Bozic M, Méndez-Barbero N, Gutiérrez-Muñoz C, Betriu A, Egido J, Fernández E, Martín-Ventura JL, Valdivielso JM, Blanco-Colio LM, investigators from the NEFRONA study.
    Atherosclerosis; 2018 Mar 31; 270():13-20. PubMed ID: 29407881
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).
    Hassannejad R, Sharrouf H, Haghighatdoost F, Kirk B, Amirabdollahian F.
    Nutrients; 2021 Jun 30; 13(7):. PubMed ID: 34209146
    [Abstract] [Full Text] [Related]

  • 15. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.
    Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2009 Nov 30; 4(11):1716-23. PubMed ID: 19820131
    [Abstract] [Full Text] [Related]

  • 16. Fermented dairy products, diet quality, and cardio-metabolic profile of a Mediterranean cohort at high cardiovascular risk.
    Mena-Sánchez G, Babio N, Martínez-González MÁ, Corella D, Schröder H, Vioque J, Romaguera D, Martínez JA, Lopez-Miranda J, Estruch R, Wärnberg J, Bueno-Cavanillas A, Serra-Majem L, Tur JA, Arós F, Tinahones FJ, Sánchez VM, Lapetra J, Pintó X, Vidal J, Vázquez C, Ordovás JM, Delgado-Rodriguez M, Matía-Martín P, Basora J, Buil-Cosiales P, Fernandez-Carrion R, Fitó M, Salas-Salvadó J, PREDIMED-PLUS investigators.
    Nutr Metab Cardiovasc Dis; 2018 Oct 30; 28(10):1002-1011. PubMed ID: 30207268
    [Abstract] [Full Text] [Related]

  • 17. The association of metabolic syndrome components and diabetes mellitus: evidence from China National Stroke Screening and Prevention Project.
    Li W, Wang D, Wang X, Gong Y, Cao S, Yin X, Zhuang X, Shi W, Wang Z, Lu Z.
    BMC Public Health; 2019 Feb 14; 19(1):192. PubMed ID: 30764803
    [Abstract] [Full Text] [Related]

  • 18. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Feb 14; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 19. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients.
    Turkmen K, Tonbul HZ, Erdur FM, Toker A, Biyik Z, Ozbiner H, Gaipov A, Gul EE, Kayrak M, Solak Y, Ozbek O, Turk S, Covic A.
    BMC Nephrol; 2013 Jul 12; 14():144. PubMed ID: 23849432
    [Abstract] [Full Text] [Related]

  • 20. Serum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patients.
    Asil M, Dertli R.
    Medicine (Baltimore); 2016 Sep 12; 95(37):e4763. PubMed ID: 27631226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.